Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 50 от 100

Набира участници

IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma

Melanoma (Skin Cancer)

This study aims to capture information regarding the effect of immune checkpoint inhibitor (ICI) treatment for melanoma on reproductive organ function and sex hormone levels. You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with melanoma (Stage II, III or IV) and you are planning to receive ICI treatment. Additional criteria will apply dependent upon your biological sex characteristics. All participants who choose to enroll in this study will be asked to complete a series of questionnaires and provide blood at 4 of their scheduled treatment visits. These visits are anticipated to add 30 minutes to the scheduled visit time. Male participants will also be asked to provide semen samples at 2 of their scheduled treatment visits. These visits are anticipated to add an additional 30 minutes to the scheduled visit time. No additional or novel treatments will be offered to participants who choose to enroll in this study, this is an observational study only. It is hoped this research will contribute important information regarding the potential toxic effects of ICI treatment on sexual and reproductive function in patients with melanoma who are receiving ICI treatment.

Начало: 11.09.2025 Край: 01.12.2027 Възраст: 18–60 г.

Australia Peter MacCallum Cancer Centre, Australia NCT07138222

Набира участници Фаза 1

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Urothelial Carcinoma Bladder Triple Negative Breast Cancer (TNBC) Hormone Receptor Positive Breast Adenocarcinoma Non Small Cell Lung Cancer +3

This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.

Начало: 22.08.2025 Край: 01.06.2032 Възраст: от 18 г.

United States Aktis Oncology, Inc. NCT07020117

Набира участници Фаза 1

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

NSCLC (Advanced Non-small Cell Lung Cancer) HNSCC CRC (Colorectal Cancer) ESCC +3

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors

Начало: 18.08.2025 Край: 01.12.2027 Възраст: от 18 г.

United States ALX Oncology Inc. NCT07085091

Набира участници Фаза 2/3

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Melanoma (Skin Cancer) Melanoma Stage IIIB-IV Cutaneous Melanoma Unresectable Melanoma

The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Researchers will compare LNS8801 taken alone or LNS8801 taken together with another drug called pembrolizumab to other therapies as decided by the treating doctor. 135 patients will be randomly (like flipping a coin) placed in 3 treatment groups. In the first group (LNS8801 only) - Patients will take 125mg tablet of LNS8801 by mouth once per day every day for up to 2 years. In the second group (LNS8801 + pembrolizumab) - Patients will take 125mg tablet of LNS8801 by mouth once per day plus 200 mg of pembrolizumab by IV infusion once every 3 weeks for up to 2 years. In the third group, called Physician's Choice (PC), patients will receive chemotherapy (dacarbazine or temozolomide) or immunotherapy (pembrolizumab, nivolumab/relatlimab or nivolumab/ipilimumab) as determined by their treating physician. How often the patient visits the clinic visits will depend on the treatment group. Besides returning to the clinic for treatment, the patient will undergo periodic safety assessments and other required study procedures such as imaging assessments.

Начало: 06.08.2025 Край: 01.02.2031 Възраст: от 18 г.

United States Linnaeus Therapeutics, Inc. NCT06624644

Набира участници Фаза 1/2

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Melanoma Non-small Cell Lung Cancer Squamous Cell Carcinoma (Skin) Renal Cell Carcinoma +5

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Начало: 29.07.2025 Край: 02.10.2029 Възраст: от 18 г. Лечение

Australia, Japan, South Korea +1 AstraZeneca NCT07115043

Набира участници Фаза 1

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor Metastatic Solid Tumor Endometrial Cancer MSI-H Cancer +3

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.

Начало: 16.07.2025 Край: 01.05.2028 Възраст: от 18 г. Лечение

Australia, United States MOMA Therapeutics NCT06974110

Набира участници

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Lung Cancer, Hepatocellular Carcinoma

This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.

Начало: 15.07.2025 Край: 31.12.2028 Възраст: от 18 г.

Austria, Belgium, Bulgaria +5 Hoffmann-La Roche NCT07284121

Набира участници

Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates - UK

Lung Cancer

This study involves the use of a medical device, the Creo Medical MicroBlate Flex instrument, to heat and destroy lung tumour cells using microwave energy (this is also called ablation). In this study, the investigators are investigating whether the ablation instrument can be used effectively to treat lung tumours or tumours that have spread to the lungs. If successful, using this technology may mean future patients may not need to undergo surgical removal of these types of lung tumours. The aim of this study is to evaluate the safety and performance of the MicroBlate Flex instrument in treating individuals with cancerous lung tumours that are due to be removed by surgery. All participants in the study will undergo the microwave ablation procedure, which is a separate and additional procedure to their surgical procedure. The study, funded by Creo Medical, will be conducted at sites in the UK and Italy, and will involve up to 18 participants.

Начало: 14.07.2025 Край: 01.12.2026 Възраст: от 18 г.

Italy, United Kingdom Creo Medical Limited NCT06869122

Набира участници Фаза 1/2

Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells

Cancer

The primary objectives are to evaluate the safety and efficacy of infusion of autologous tumor associated antigen-specific engineered immune effector cells (EIE).

Начало: 01.07.2025 Край: 31.12.2029 Възраст: 1–80 г.

China Shenzhen Geno-Immune Medical Institute NCT03535246

Набира участници Фаза 1/2

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Pancreatic Ductal Adenocarcinoma Non Small Cell Lung Cancer Colorectal Cancer Solid Tumor, Adult +1

This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

Начало: 24.06.2025 Край: 01.12.2028 Възраст: от 18 г. Лечение

Australia, United States Verastem, Inc. NCT07020221

Набира участници Фаза 1/2

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

PDAC PDAC - Pancreatic Ductal Adenocarcinoma NSCLC RAS Mutation +4

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.

Начало: 31.05.2025 Край: 01.12.2027 Възраст: от 18 г.

United States Tango Therapeutics, Inc. NCT06922591

Набира участници Фаза 1

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Non Small Cell Lung Cancer

This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.

Начало: 13.05.2025 Край: 01.12.2028 Възраст: от 18 г. Лечение

Australia, United States Dizal Pharmaceuticals NCT06905197

Набира участници Фаза 1

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

Prostate Cancer

A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Начало: 08.05.2025 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, United States SURGE Therapeutics NCT06450106

Набира участници Фаза 3

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NSCLC (Non-small Cell Lung Cancer) Non-Small Cell Lung Cancer NSCLC NSCLC (Non-small Cell Lung Carcinoma) +1

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Начало: 06.05.2025 Край: 01.12.2030 Възраст: от 18 г. Лечение

Australia, Belgium, France +16 Revolution Medicines, Inc. NCT06881784

Набира участници Фаза 1/2

Study for AZD4360 in Participants With Advanced Solid Tumours

Gastric Cancer Gastroesophageal Junction Cancer Biliary Tract Cancer Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.

Начало: 29.04.2025 Край: 16.12.2027 Възраст: 18–130 г.

China, Germany, Japan +2 AstraZeneca NCT06921928

Набира участници Фаза 2

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

Fungal Infection Haematological Malignancy Blood Cancer Infectious Disease

This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally effective dosing regimens. This study investigates if voriconazole increases the proportion of patients achieving therapeutic exposure at day 8 of dosing compared with standard care; and will assess factors that influence the implementation of genotype testing and dosing software in the healthcare system, including fidelity, feasibility, acceptability and cost-effectiveness. It will recruit at least 104 kids and adults in a parallel-group randomised clinical trial. A hybrid feasibility sub-study will assess the scalability of genotype-directed dosing to ensure sustainable integration of the interventions into the clinical workflow. A health economic sub-study will evaluate the costs, health outcomes and cost-effectiveness of genotype-directed testing compared to standard care.

Начало: 14.04.2025 Край: 26.03.2027 Възраст: от 2 г. Лечение

Australia, United States The University of Queensland NCT06510699

Набира участници Фаза 1/2

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Advanced Solid Tumors Cancer MSI-H Cancer

The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? What kind of effects does NDI-219216 have on the body? Does NDI-219216 have any impact on tumor size? Participants will: Take NDI-219216 every day by mouth. Visit the clinic 6 times during Cycle 1, 2 times during Cycle 2, once a month thereafter for checkups and tests while on the study, then one time for an end of treatment visit. After the End of Study, a follow up will occur but can be done on the phone. Keep a diary of their tablet consumption and symptoms experienced.

Начало: 31.03.2025 Край: 01.12.2031 Възраст: 18–99 г. Лечение

Australia, Canada, France +5 Nimbus Wadjet, Inc. NCT06898450

Набира участници

Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma

Ovarian Cancer

Ovarian carcinoma is the most lethal gynecological malignancy. Epithelial ovarian carcinoma is the gynecological malignancy with the highest mortality rate. The prognosis of patients with recurrent disease is highly heterogeneous and is typically poor in cases of ovarian carcinoma with a progression-free survival (PFS) ≤ 6 months, for which therapeutic options are limited. However, it has been shown that patients with a PFS ≤ 6 months may not respond effectively to further treatments, whereas, conversely, patients with a PFS \> 6 months could still benefit from them. The classification of patients with recurrent disease has undergone continuous evolution over time. Essential factors to consider include patient characteristics, disease stage, and the precise genetic and molecular profile of the tumor. This study aims to evaluate survival in patients experiencing recurrence of epithelial ovarian carcinoma with an unfavorable prognosis, with the objective of improving patient categorization and management.

Начало: 24.03.2025 Край: 01.03.2027 Възраст: от 18 г.

Italy Fondazione Policlinico Universitario Agostino Gemelli I NCT07540403

Набира участници

Mg OSTEOCRETE Post-Treatment Outcomes

Cancer of Bone Trauma Aseptic Loosening of Orthopaedic Hardware

Mg OSTEOCRETE is a bone substitute used to fill a defect in bone caused by excision of a tumor, orthopaedic hardware that has become loosened, or a trauma-related condition. The aim of this study is to determine the amount of time it takes for bone to heal after treatment with Mg OSTEOCRETE, and to better understand the efficacy of this treatment through clinical and patient-reported outcomes.

Начало: 17.03.2025 Край: 17.03.2028 Възраст: от 18 г.

United States Santiago Lozano-Calderon NCT06720142

Набира участници Фаза 2/3

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Prostate Cancer

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment

Начало: 27.02.2025 Край: 19.07.2033 Възраст: 18–100 г. Лечение

Australia, Brazil, China +8 Novartis Pharmaceuticals NCT06780670

1 … 48 49 50 51 52 … 100